No Prescription |
 |
 | ||
|
Evalon Vaginal Cream Ovestin |
|
| ||
No Prescription » Prescription Drugs 7 » Evalon Vaginal Cream Ovestin Evalon used in the treatment of vaginal complaints such as dyspareunia dryness and itching. Evalon used for the prevention of recurrent infections of the vagina and lower urinary tract. Evalon used in the management of micturition complaints (such as frequency and dysuria) and mild urinary incontinence.Pre- and post-operative therapy in postmenopausal women undergoing vaginal surgery. Buy Evalon Vaginal Cream Ovestin and other Prescription Drugs 7 products online at Medstore. 2133
About Evalon Vaginal Cream Ovestin: Product Type: Prescription Drugs 7 Evalon Vaginal Cream( Ovestin Generic Estriol ) Evalon Vaginal Cream (Ovestin Generic Estriol) Ovestin Generic Estriol 1mg/gm cream 2 x 15gm Ovestin Generic Estriol Evalon Vaginal Cream
View more Prescription Drugs 7 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
